These findings are echoed by the ORAL Surveillance trial, which compared TOFA with TNF inhibitors (adalimumab at a dose of 40 mg every 2 weeks or etanercept at a dose of 50 mg once weekly) in patients with RA and no history of cancer. The gene discussed is TNF; the disease is cancer.